论文部分内容阅读
[目的]研究中药复方胃安泰胶囊对胃癌前病变(PLGC)大鼠胃黏膜细胞核仁组成区嗜银蛋白(Ag-NORs)水平的影响,并探讨其可能的防治PLGC作用机制。[方法]采用综合造模法建立PLGC大鼠模型。造模前,将大鼠随机分为正常组、预防组、造模组。预防组在造模的同时灌服胃安泰胶囊,最后和其他组进行比较。确认造模成功后大鼠随机分为正常组,预防组,胃安泰高、中、低剂量组,维酶素组和病理对照组,以胃安泰胶囊(不同剂量)分别对高、中、低剂量组大鼠进行灌胃,以维酶素片作为西药对照。实验结束后摘取胃,测定胃黏膜AgNORs颗粒的水平。[结果]经胃安泰胶囊治疗后,PLGC大鼠胃黏膜AgNORs颗粒数明显减少,疗效优于维霉素组(P<0.01);预防组大鼠胃黏膜AgNORs颗粒数明显少于病理对照组(P<0.01)。[结论]胃安泰胶囊对胃癌前期病变有很好的预防和逆转作用。
[Objective] To investigate the effect of the Chinese medicine compound Weiantai capsule on the level of Ag-NORs in gastric mucosal cells of gastric precancerous lesions (PLGC) and to explore its possible mechanism of preventing and treating PLGC. [Method] The PLGC rat model was established by comprehensive modeling method. Before modeling, rats were randomly divided into normal group, prevention group and model group. Prevention group in the modeling at the same time stomach Wei Tai Capsule, and finally compared with other groups. After confirming the success of modeling, rats were randomly divided into normal group, prophylaxis group, Weitai high, medium and low dose groups, Verapamil group and pathological control group, with Weiantai capsule (different doses) The rats in the dose group were given gavage, and the enzyme tablets were used as the western medicine control. After the experiment, the stomach was taken and the level of AgNORs particles in gastric mucosa was measured. [Result] The results showed that the number of AgNORs particles in gastric mucosa of PLGC rats was significantly reduced after treatment with Weiantai capsule, and the effect was better than that of the other groups (P <0.01). The number of AgNORs particles in gastric mucosa of rats in prevention group was obviously less than that of the control group P <0.01). [Conclusion] Weiantai capsule has a good preventive and reversal effect on gastric precancerous lesions.